journal cover

Recent Advances in the Drug Treatment of Dravet Syndrome

CNS Drugs

Sep 25, 2019

Elaine C Wirrell, Rima Nabbout

Abstract

Dravet syndrome is a rare but severe epilepsy syndrome that begins in the first year of life with recurrent seizures triggered by fever that are typically prolonged and hemiclonic. The epilepsy is highly drug resistant. Although development is normal at onset, over time, most patients d...read more

Mentioned in this Paper

Fenfluramine
Infantile Severe Myoclonic Epilepsy
Epilepsy
Channelopathies
Cessation of Life
Adverse Effects
Pharmacologic Substance
Pharmacotherapy
Pharmaceutical Preparations
Cannabidiol
1
14
Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.

Similar Papers Found In These Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Drug Resistant Epilepsy

Drug-resistant epilepsy, also known as refractory or pharmacoresistant epilepsy, is defined as failure of adequate trials of two appropriate and tolerated antiepileptic drugs (as monotherapies or in combination) to achieve sustained seizure freedom. Discover the latest research on drug-resistant epilepsy here.

Dravet Syndrome

Dravet syndrome, previously known as severe myoclonic epilepsy of infancy (SMEI), is a rare, catastrophic, lifelong form of epilepsy with frequent and/or prolonged seizures that are often triggered by hot temperatures or fever. Discover the latest research on Dravet syndrome here.

Drug & Digital Interventions

This feed describes how digital interventions, which are digital and mobile technologies used to support health system needs, can complement and improve pharmacotherapy in disease management. Discover the latest research on drug and digtial intervention here,

Antisense Oligonucleotide - Therapies For ALS

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Epilepsy

Epilepsy is a chronic neurological disorder characterized by unprovoked and recurrent seizures. Discover the latest research on factors and mechanisms that underlie epilepsy here.

© 2020 Meta ULC. All rights reserved

Recent Advances in the Drug Treatment of Dravet Syndrome

CNS Drugs

Sep 25, 2019

Elaine C Wirrell, Rima Nabbout

PMID: 31549357

DOI: 10.1007/s40263-019-00666-8

Abstract

Dravet syndrome is a rare but severe epilepsy syndrome that begins in the first year of life with recurrent seizures triggered by fever that are typically prolonged and hemiclonic. The epilepsy is highly drug resistant. Although development is normal at onset, over time, most patients d...read more

Mentioned in this Paper

Fenfluramine
Infantile Severe Myoclonic Epilepsy
Epilepsy
Channelopathies
Cessation of Life
Adverse Effects
Pharmacologic Substance
Pharmacotherapy
Pharmaceutical Preparations
Cannabidiol
1
14

Similar Papers Found In These Feeds

Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.
/papers/recent-advances-in-the-drug-treatment-of-dravet/31549357